Hamutal Meiri

Title: Hamutal Meiri: Innovator in Maternal Health

Introduction

Hamutal Meiri is a prominent inventor based in Tel Aviv, Israel. She has made significant contributions to the field of maternal health, particularly in the early detection and treatment of preeclampsia and related conditions. With a total of 4 patents, her work is paving the way for improved outcomes for pregnant women.

Latest Patents

One of her latest patents focuses on a biomarker test for the prediction or early detection of preeclampsia and/or HELLP syndrome. This invention discloses specific biomarkers that enable early testing, providing a method to predict preeclampsia in pregnant women. Additionally, it includes a kit designed for assaying samples from pregnant women to measure the concentrations of these biomarkers. Another significant patent relates to the biological activity of placental protein 13 (PP-13). This invention explores the biological and pharmacological effects of PP-13, which may be utilized for the treatment and prevention of preeclampsia and placental insufficiencies in pregnant female mammals. The method aims to precondition uterine arteries to prevent or reverse pathological conditions associated with placental insufficiency.

Career Highlights

Throughout her career, Hamutal Meiri has worked with notable organizations such as Diagnostic Technologies Ltd. and Wayne State University. Her experience in these institutions has contributed to her expertise in maternal health innovations.

Collaborations

Hamutal has collaborated with esteemed colleagues, including Adi L Tarca and Nandor Than. These partnerships have further enhanced her research and development efforts in the field.

Conclusion

Hamutal Meiri's innovative work in maternal health is making a significant impact on the early detection and treatment of preeclampsia. Her contributions are vital for improving the health and safety of pregnant women.